4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data and Program Update Call Transcript
Hello, ladies and gentlemen. Thank you for standing by, and welcome to 4D Molecular Therapeutics Webcast Presentation of Interim Safety and Efficacy Data from the Phase I/II AEROW Clinical Trial of Aerosolized 4D-710 for the treatment of cystic fibrosis lung disease. (Operator Instructions) As a reminder, today's call is being recorded.
With that, I will hand the call over to Uneek Mehra, Chief Financial and Business Officer, who will make introductory comments.
Thank you, operator, and welcome, everyone, to our webcast. A press release describing the results and development plans related to 4D-710 is accessible in the Investors section of the 4DMT website, and a recording of this webcast will also be accessible on our website after the completion of this call.
With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer, who will provide introductory remarks. Dr. Alan Cohen, who recently joined 4DMT as SVP, Therapeutic Area Head of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
